港股異動丨寶蘭德(688058.SH)漲超6%創17個月新高 2021年淨利預增超5成
格隆匯1月25日丨寶蘭德(688058.SH)再度拉昇漲6.13%,月內累計飆升近60%。現報127.92元創17個月新高價,成交額放大至1.67億元,總市值超50億元。公司預計2021年年度歸母淨利為9200萬元到1.05億元,同比增加50.68%到71.98%。報吿期內黨政客户帶來的收入預計較上年同期增長明顯,同時伴隨金融客户覆蓋率快速提升,預計金融客户帶來的收入較上年同期大幅增長。據悉,公司日前獲選“2021中國信創產業應用落地供應商TOP60”,彰顯了寶蘭德在基礎軟件領域的技術服務實力,同時也是推動基礎軟件國產化,助力企業數字化轉型成績的認可。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.